Cefotaxime is a third-generation cephalosporin with excellent in vitro antimicrobial activity against Neisseria gonorrhoeae, including beta-lactamase-producing strains. A single 1-g intramuscular dose is suitable for the treatment of uncomplicated gonorrhea. We conducted an open, randomized study to evaluate the efficacy, safety, and cost impact of a lower dose (500 mg) of cefotaxime versus 250 mg ceftriaxone, an often recommended treatment for uncomplicated gonorrhea. Of the 222 patients enrolled, the cases of 151 were fully assessable. Bacteriologic elimination rates were 99% in the cefotaxime group and 100% in the ceftriaxone group. Clinical response rates were 78% and 83% in the two groups, respectively. Adverse clinical events occurred in 4% and 9% of patients in the two groups, respectively. The average wholesale price of 500 mg cefotaxime is 31% lower than that of 250 mg ceftriaxone. A 500-mg dose of cefotaxime appears to be a safe and cost-effective alternative to 250 mg ceftriaxone for the treatment of uncomplicated gonorrhea.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00007611-199404000-00007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Variability in the Evaluation and Treatment of Healthy Neonates With Uncomplicated Conjunctivitis.
J Pediatr Ophthalmol Strabismus
December 2024
Purpose: To explore the current state of diagnosis and management of neonatal conjunctivitis.
Methods: Cosmos, an EHR-based, de-identified data set including more than 200 million patients, was used for this study. Neonates born between January 1, 2016 and December 31, 2022, discharged from the hospital by day 3 of life, and with an ambulatory visit within the first 4 weeks of life associated with a new diagnosis of neonatal conjunctivitis (SNOMED) or conjunctivitis (ICD-10 H10.
Recommendations for the optimal introduction of novel antibiotics to treat uncomplicated gonorrhoea in the face of increasing antimicrobial resistance: a case study with zoliflodacin.
BMC Glob Public Health
September 2024
Global Antibiotic Research & Development Partnership, Geneva, Switzerland.
New, first-in-class oral antibiotics like zoliflodacin, developed in a public-private partnership, require an optimal introduction strategy while ensuring antibiotic stewardship. Zoliflodacin, given as a single dose for uncomplicated urogenital gonorrhoea, recently demonstrated non-inferiority to ceftriaxone plus azithromycin and safety in a phase 3 randomised controlled trial. Following regulatory approval, zoliflodacin could improve sexually transmitted infection (STI) management and help address the threat of untreatable gonorrhoea, as levels of resistance to current first-line treatments increase.
View Article and Find Full Text PDF[Do not overuse doxycycline as prophylaxis for uncomplicated sexually transmitted infections].
Lakartidningen
August 2024
med dr, överläkare, infektionssjukdomar, medicinskt ledningsansvarig läkare, Venhälsan, infektionskliniken, Södersjukhuset.
STI prophylaxis using doxycycline is discussed internationally for persons at high risk of STIs (Doxy-PEP). Doxy-PEP would probably have limited effect on gonorrhoea due to resistance to tetracyclines. Doxy-PEP may reduce the incidence of chlamydia and syphilis, but would not reduce the number of complicated infections.
View Article and Find Full Text PDFInteractions between Zoliflodacin and Gyrase and Topoisomerase IV: Enzymological Basis for Cellular Targeting.
ACS Infect Dis
August 2024
Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Article Synopsis
- * Spiropyrimidinetriones (SPTs), like zoliflodacin, have been developed to fight this resistance and show effectiveness against uncomplicated gonorrhea during human trials.
- * Zoliflodacin is more potent against gyrase than topoisomerase IV, producing more DNA cleavage, and the new SPT H3D-005722 shows promise for achieving balanced targeting of both enzymes.
Background: The indiscriminate use of antibiotics has accelerated antimicrobial resistance (AMR) in (), emphasising the need to follow treatment guidelines. This study aimed to assess the rate of adherence to standard treatment among patients with gonorrhoea and identify influencing factors.
Methods: A survey was conducted in Guangdong province, China, involving uncomplicated gonorrhoea cases registered in the Chinese Information System for Disease Control and Prevention.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!